Three-year data from the PALISADE study of plozasiran in patients with genetically confirmed familial chylomicronaemia syndrome (FCS), and pooled data from the SHASTA-3 and SHASTA-4 studies in patients with severe hypertriglyceridaemia (sHTG) have confirmed the sustained TG lowering reported at previous stages of the trials and reductions in acute pancreatitis (AP).
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
